Quadrant Capital Group’s Collegium Pharmaceutical COLL Stock Holding History

Quadrant Capital Group’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$243K	Sell	6,714 -286	-4%	-$9.77K	0.01%	1155
2026 Q1	$231K	Buy	7,000 +4	+0.1%	+$169	0.01%	1221
2025 Q4	$324K	Buy	6,996 +282	+4%	+$11.8K	0.01%	1126
2025 Q3	$235K	Buy	+6,714	New	+$233K	0.01%	1218
2025 Q2	–	Sell	-7,218	Closed	-$215K	–	1614
2025 Q1	$215K	Buy	7,218 +7,076	+4,983%	+$216K	0.01%	1256
2024 Q4	$4.07K	Hold	142	–	–	﹤0.01%	2354
2024 Q3	$5.49K	Hold	142	–	–	﹤0.01%	2298
2024 Q2	$4.57K	Hold	142	–	–	﹤0.01%	2313
2024 Q1	$5.51K	Hold	142	–	–	﹤0.01%	2283
2023 Q4	$4.37K	Sell	142 -17	-11%	-$426	﹤0.01%	2310
2023 Q3	$3.55K	Buy	159 +17	+12%	+$388	﹤0.01%	2257
2023 Q2	$3.05K	Sell	142 -16	-10%	-$363	﹤0.01%	2319
2023 Q1	$3.79K	Buy	158 +16	+11%	+$424	﹤0.01%	2291
2022 Q4	$3.29K	Buy	142 +123	+647%	+$2.48K	﹤0.01%	2302
2022 Q3	$0	Buy	+19	New	+$335	﹤0.01%	2656
2022 Q2	–	Sell	-22	Closed	–	–	2568
2022 Q1	$0	Buy	+22	New	+$416	﹤0.01%	2518

Other funds holding COLL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Quadrant Capital Group's COLL Position: Q2 2026 in Review

Quadrant Capital Group reduced its Collegium Pharmaceutical (COLL) stake by 4.1% in Q2 2026, selling an estimated $9.77K and leaving 6,714 shares worth $243K. The position accounts for 0.01% of the portfolio, ranked #1155.

Quadrant Capital Group first reported a position in COLL in Q1 2022 and has held it in 16 quarters since. The position peaked at $324K in Q4 2025. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

Quadrant Capital Group held 6,714 shares of Collegium Pharmaceutical worth $243K as of Q2 2026.
Quadrant Capital Group sold 286 Collegium Pharmaceutical shares in Q2 2026, an estimated $9.77K.
Collegium Pharmaceutical made up 0.01% of Quadrant Capital Group's portfolio in Q2 2026, its #1155 holding.
Quadrant Capital Group first reported a position in Collegium Pharmaceutical in Q1 2022 and has held it in 16 quarters since.
Quadrant Capital Group's Collegium Pharmaceutical position peaked at $324K in Q4 2025.
279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.